Lergonix

Bilastine, the active ingredient in Lergonix, is a second‑generation antihistamine presented as a tablet for oral use. It treats allergic rhinitis and chronic idiopathic urticaria in adults and adolescents. GNH USA supplies Lergonix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lergonix, a second‑generation H1‑antagonist, is used to manage allergic conditions by blocking peripheral histamine receptors. Allergic rhinitis: reduces nasal congestion, itching and sneezing associated with seasonal or perennial allergies. Chronic idiopathic urticaria: alleviates wheals and itching in patients with persistent hives of unknown cause. Seasonal allergic conjunctivitis: helps control eye itching and redness caused by pollen exposure.

Bilastine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported during early treatment. - Dry mouth: sensation of oral dryness without actual salivary loss. - Drowsiness: occasional mild sedation, less frequent than first‑generation antihistamines. - Fatigue: feeling of reduced energy or tiredness. - Nausea: mild stomach upset or queasiness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Stevens‑Johnson syndrome: rare skin blistering and mucosal involvement. - Hepatotoxicity: abnormal liver function tests or jaundice. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Severe hypotension: marked drop in blood pressure. - Hematologic abnormalities: rare blood cell count changes.

Before initiating therapy with Lergonix, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: discuss potential risks with a physician before use. - Renal impairment: dose adjustment may be required in severe kidney dysfunction. - Elderly patients: monitor for increased CNS effects such as drowsiness. - Concomitant medications: review all current drugs for possible interactions. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Bilastine may interact with several medicines; awareness helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition can raise bilastine plasma levels. - Erythromycin: macrolide antibiotics may increase bilastine exposure. - Diltiazem: calcium‑channel blocker may elevate bilastine concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: additive sedative effect may enhance drowsiness. - Other antihistamines: combined use can increase risk of anticholinergic side effects. - CNS depressants: may potentiate central nervous system depression. - Grapefruit juice: can modestly affect bilastine metabolism. - Rifampicin: enzyme induction may reduce bilastine effectiveness.